# Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

> **NCT02770014** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 43 (actual)

## Conditions studied

- Epidermal Growth Factor Receptor
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT02770014
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2019-04-16
- **Final completion:** 2019-06-19
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Terminated due to Osimertinib approval
- **Last updated:** 2019-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02770014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02770014, "Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02770014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*